The pharmacogenomics theranostics market is segmented by application, technology, end-user, and geography. By application, the segmentation goes like cardiovascular disease, pain management, psychiatry, infectious diseases, oncology, and neurological disease. By technology, the pharmacogenomics technology industry spans sequencing, polymerase chain reaction, mass spectrometry, microarray, and electrophoresis. By end-user, the pharmacogenomics companion diagnostics (CDx) market states research organizations & academic institutes and hospitals and clinics. By geography, it comprises North America, Asia Pacific, LATAM, Europe, and MEA.
Download Free Sample - https://www.millioninsights.com/industry-reports/pharmacogenomics-technology-market/request-sample
North America rules the roost; thanks to extensive investment in healthcare by the U.S. Europe comes in second due to Belgium and Denmark being on the top pedestal with respect to healthcare. Asia Pacific is expected to grow at the fastest pace owing to increase in awareness among the economies like India and China regarding healthcare. LATAM will also catch up due to presence of Brazil; followed by MEA. In fact, MEA would be more vigilant on this count; due to the figures released by WHO. It says that over 50% of the diseases mentioned above occur in sub-Saharan Africa.
Players:
The players contributing to the pharmacogenomics technology market include OPKO Health, Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceutical Industries Ltd., Dynamic DNA Laboratories, Abbott Laboratories, F. Hoffmann-La Roche Ltd., One Ome LLC, Empire Genomics, LLC, and Illumina, Inc.
Comments
Post a Comment